Local application of recombinant active-site inhibited human clotting factor VIIa reduces thrombus weight and improves patency in a rabbit venous thrombosis model
(1998) In European Journal of Vascular and Endovascular Surgery 15(6). p.515-520- Abstract
Objective: To study whether locally administered recombinant inactivated human coagulation factor VIIa (FFR-rFVIIa) would reduce the thrombus formation and improve patency in an experimental venous thrombosis model without inducing systematic changes in the coagulation. Design: Experimental double-dummy randomised study. Materials: In 20 healthy New Zealand White rabbits both juguIar veins were exposed under general anaesthesia. Methods: The thrombi were induced in a 10 mm long jugular vein segment with a combination of chemical destruction of the intima and a restriction of the bloodflow. Each segment was treated with either FFR-rFVIIa or placebo injected directly into the vein. Results: 1.5 mg topically applied FFR-rFVIIa... (More)
Objective: To study whether locally administered recombinant inactivated human coagulation factor VIIa (FFR-rFVIIa) would reduce the thrombus formation and improve patency in an experimental venous thrombosis model without inducing systematic changes in the coagulation. Design: Experimental double-dummy randomised study. Materials: In 20 healthy New Zealand White rabbits both juguIar veins were exposed under general anaesthesia. Methods: The thrombi were induced in a 10 mm long jugular vein segment with a combination of chemical destruction of the intima and a restriction of the bloodflow. Each segment was treated with either FFR-rFVIIa or placebo injected directly into the vein. Results: 1.5 mg topically applied FFR-rFVIIa significantly reduced the thrombus weight (p < 0.001). The 30 and the 120 min patency tests were significantly improved (p < 0.05 and p < 0.001, respectively). Plasma analyses (APTT, dilute-TF time, FVII protein) were evaluated as baseline, 3 min after declamping and at sacrifice. No prolongation of the clotting times were seen. FFR-rFVIIa protein was detected in minute amounts (ng/ml); however, this was not enough to prolong the dilute-TF time. Conclusions: Local application of recombinant active-site inhibited human FVIIa reduced both thrombus weight and improved patency significantly in an experimental venous thrombosis model without affecting the systematic clotting times.
(Less)
- author
- Holst, J. LU ; Kristensen, A. T. ; Kristensen, H. I. ; Ezban, M. and Hedner, U. LU
- publishing date
- 1998
- type
- Contribution to journal
- publication status
- published
- keywords
- FVIIa, Inactivated FVIIa, Patency, TF, TF-FVII-dependent coagulation, Venous thrombosis
- in
- European Journal of Vascular and Endovascular Surgery
- volume
- 15
- issue
- 6
- pages
- 515 - 520
- publisher
- Elsevier
- external identifiers
-
- pmid:9659887
- scopus:0031876354
- ISSN
- 1078-5884
- DOI
- 10.1016/S1078-5884(98)80112-3
- language
- English
- LU publication?
- no
- id
- 1cfd718a-0acf-4d40-b5cd-f8e684851e2a
- date added to LUP
- 2018-04-05 15:43:49
- date last changed
- 2024-05-27 09:40:48
@article{1cfd718a-0acf-4d40-b5cd-f8e684851e2a, abstract = {{<p>Objective: To study whether locally administered recombinant inactivated human coagulation factor VIIa (FFR-rFVIIa) would reduce the thrombus formation and improve patency in an experimental venous thrombosis model without inducing systematic changes in the coagulation. Design: Experimental double-dummy randomised study. Materials: In 20 healthy New Zealand White rabbits both juguIar veins were exposed under general anaesthesia. Methods: The thrombi were induced in a 10 mm long jugular vein segment with a combination of chemical destruction of the intima and a restriction of the bloodflow. Each segment was treated with either FFR-rFVIIa or placebo injected directly into the vein. Results: 1.5 mg topically applied FFR-rFVIIa significantly reduced the thrombus weight (p < 0.001). The 30 and the 120 min patency tests were significantly improved (p < 0.05 and p < 0.001, respectively). Plasma analyses (APTT, dilute-TF time, FVII protein) were evaluated as baseline, 3 min after declamping and at sacrifice. No prolongation of the clotting times were seen. FFR-rFVIIa protein was detected in minute amounts (ng/ml); however, this was not enough to prolong the dilute-TF time. Conclusions: Local application of recombinant active-site inhibited human FVIIa reduced both thrombus weight and improved patency significantly in an experimental venous thrombosis model without affecting the systematic clotting times.</p>}}, author = {{Holst, J. and Kristensen, A. T. and Kristensen, H. I. and Ezban, M. and Hedner, U.}}, issn = {{1078-5884}}, keywords = {{FVIIa; Inactivated FVIIa; Patency; TF; TF-FVII-dependent coagulation; Venous thrombosis}}, language = {{eng}}, number = {{6}}, pages = {{515--520}}, publisher = {{Elsevier}}, series = {{European Journal of Vascular and Endovascular Surgery}}, title = {{Local application of recombinant active-site inhibited human clotting factor VIIa reduces thrombus weight and improves patency in a rabbit venous thrombosis model}}, url = {{http://dx.doi.org/10.1016/S1078-5884(98)80112-3}}, doi = {{10.1016/S1078-5884(98)80112-3}}, volume = {{15}}, year = {{1998}}, }